{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:35:18Z","timestamp":1790638518902,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["13435"],"award-info":[{"award-number":["13435"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A minority of Colorectal Cancer (CRC) patients with peritoneal metastases is eligible for cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC). However, recurrence rates are high (~80%). We tested whether inhibitors of the DNA damage response (DDR) could prevent recurrence in an in vitro HIPEC model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Peritoneal metastasis-derived organoids (PMDOs;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) were treated with inhibitors of ATR (berzosertib, ceralasertib, elimusertib), CHK1 (rabusertib), and WEE1 (adavosertib) alone, and in combination with MMC, oxaliplatin, or irinotecan. Western blotting was used to determine Chk1 phosphorylation and markers of DNA damage. Microscopy and ATP quantification were used to measure the effects of (combination) treatments on cell viability and recurrence\/regrowth.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All PMDOs displayed rapid regrowth (recurrence) following single-drug chemotherapy treatment. Berzosertib inhibited chemotherapy-induced CHK1 phosphorylation, augmented DNA damage, and abrogated recurrence in all 10 MMC-treated PMDOs. The combination with oxaliplatin and irinotecan was less effective. In vitro HIPEC with MMC, followed by \u2018adjuvant\u2019 treatment with any of the DDR inhibitors for 3 days, completely prevented PMDO recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PMDOs can be completely eradicated if MMC treatment is followed by inhibition of ATR or other DDR kinases. DDR inhibitors may therefore have value in the adjuvant treatment of peritoneal metastases following CRS-HIPEC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03310-z","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:27:47Z","timestamp":1767619667000},"page":"831-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0870-788X","authenticated-orcid":false,"given":"Kyah","family":"van Megesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelief","family":"Kieboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M. L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inne","family":"Borel Rinkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-4390","authenticated-orcid":false,"given":"Onno","family":"Kranenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"3310_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650098","volume":"11","author":"O Kranenburg","year":"2021","unstructured":"Kranenburg O, van der Speeten K, de Hingh I. Peritoneal metastases from colorectal cancer: defining and addressing the challenges. Front Oncol. 2021;11:650098.","journal-title":"Front Oncol"},{"key":"3310_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.suc.2017.01.013","volume":"97","author":"B Hall","year":"2017","unstructured":"Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am. 2017;97:671\u201382.","journal-title":"Surg Clin North Am"},{"key":"3310_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejca.2016.07.002","volume":"65","author":"LGEM Razenberg","year":"2016","unstructured":"Razenberg LGEM, Lemmens VEPP, Verwaal VJ, Punt CJA, Tanis PJ, Creemers G-J, et al. Challenging the dogma of colorectal peritoneal metastases as an untreatable condition: results of a population-based study. Eur J Cancer. 2016;65:113\u201320.","journal-title":"Eur J Cancer"},{"key":"3310_CR4","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1245\/s10434-013-3145-9","volume":"20","author":"AMJ Kuijpers","year":"2013","unstructured":"Kuijpers AMJ, Mirck B, Aalbers AGJ, Nienhuijs SW, de Hingh IHJT, Wiezer MJ, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224\u201330.","journal-title":"Ann Surg Oncol"},{"key":"3310_CR5","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol"},{"key":"3310_CR6","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer. 2010;116:5608\u201318.","journal-title":"Cancer"},{"key":"3310_CR7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332.","journal-title":"Ann Surg Oncol"},{"key":"3310_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/psp4.13136","volume":"13","author":"PCS Rietveld","year":"2024","unstructured":"Rietveld PCS, Sassen SDT, Guchelaar NAD, van Eerden RAG, de Boer NL, van den Heuvel TBM, et al. Population pharmacokinetics of intraperitoneal irinotecan and SN-38 in patients with peritoneal metastases from colorectal origin. CPT Pharmacomet Syst Pharm. 2024;13:1006\u201316.","journal-title":"CPT Pharmacomet Syst Pharm"},{"key":"3310_CR9","doi-asserted-by":"publisher","first-page":"7814","DOI":"10.1245\/s10434-023-13941-2","volume":"30","author":"M Raoof","year":"2023","unstructured":"Raoof M, Whelan RL, Sullivan KM, Ruel C, Frankel PH, Cole SE, et al. Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA. Ann Surg Oncol. 2023;30:7814\u201324.","journal-title":"Ann Surg Oncol"},{"key":"3310_CR10","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamasurg.2021.1642","volume":"156","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Bakkers C, Nienhuijs SW, Burger JWA, Creemers G-JM, Thijs AMJ, et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases: a phase 2 randomized clinical trial. JAMA Surg. 2021;156:710\u201320.","journal-title":"JAMA Surg"},{"key":"3310_CR11","doi-asserted-by":"publisher","first-page":"S242","DOI":"10.21037\/jgo-20-257","volume":"12","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Rovers KP, Nienhuijs SW, Creemers G-J, Burger JWA, de Hingh IHJ. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-OX) in patients with colorectal peritoneal metastases\u2014a systematic review. J Gastrointest Oncol. 2021;12:S242\u201358.","journal-title":"J Gastrointest Oncol"},{"key":"3310_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008;9:616\u201327.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3310_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41568-018-0034-3","volume":"18","author":"E Lecona","year":"2018","unstructured":"Lecona E, Fernandez-Capetillo O. Targeting ATR in cancer. Nat Rev Cancer. 2018;18:586\u201395.","journal-title":"Nat Rev Cancer"},{"key":"3310_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi NYL, Pili\u00e9 PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024;21:278\u201393.","journal-title":"Nat Rev Clin Oncol"},{"key":"3310_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.828684","volume":"12","author":"AB Bukhari","year":"2022","unstructured":"Bukhari AB, Chan GK, Gamper AM. Targeting the DNA damage response for cancer therapy by inhibiting the kinase Wee1. Front Oncol. 2022;12:828684.","journal-title":"Front Oncol"},{"key":"3310_CR16","doi-asserted-by":"publisher","unstructured":"Lin ZP, Zhu Y-L, Ratner ES. Targeting cyclin-dependent kinases for treatment of gynecologic cancers. Front Oncol. 2018;8. https:\/\/doi.org\/10.3389\/fonc.2018.00303.","DOI":"10.3389\/fonc.2018.00303"},{"key":"3310_CR17","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","volume":"21","author":"LM Karnitz","year":"2015","unstructured":"Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21:4780\u20135.","journal-title":"Clin Cancer Res"},{"key":"3310_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107450","volume":"207","author":"A Bradbury","year":"2020","unstructured":"Bradbury A, Hall S, Curtin N, Drew Y. Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations? Pharm Ther. 2020;207:107450.","journal-title":"Pharm Ther"},{"key":"3310_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/genes7080051","volume":"7","author":"J Zhang","year":"2016","unstructured":"Zhang J, Dai Q, Park D, Deng X. Targeting DNA replication stress for cancer therapy. Genes. 2016;7:51.","journal-title":"Genes"},{"key":"3310_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78\u201394.","journal-title":"Nat Rev Cancer"},{"key":"3310_CR21","first-page":"309","volume":"21","author":"N Geifman","year":"2016","unstructured":"Geifman N, Butte AJ. Do cancer clinical trial populations truly represent cancer patients? A comparison of open clinical trials to the Cancer Genome Atlas. Pac Symp Biocomput Pac Symp Biocomput. 2016;21:309\u201320.","journal-title":"Pac Symp Biocomput Pac Symp Biocomput"},{"key":"3310_CR22","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13046-021-01970-2","volume":"40","author":"G Rizzo","year":"2021","unstructured":"Rizzo G, Bertotti A, Leto SM, Vetrano S. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. J Exp Clin Cancer Res. 2021;40:178.","journal-title":"J Exp Clin Cancer Res"},{"key":"3310_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-019-0255-2","volume":"17","author":"HCH Lau","year":"2020","unstructured":"Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17:203\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3310_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407\u201318.","journal-title":"Nat Rev Cancer"},{"key":"3310_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fern\u00e1ndez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920\u20136.","journal-title":"Science"},{"key":"3310_CR26","doi-asserted-by":"publisher","unstructured":"Witte CJ de, Valle-Inclan JE, Hami N, L\u00f5hmussaar K, Kopper O, Vreuls CPH, et al. Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses. Cell Rep. 2020;31. https:\/\/doi.org\/10.1016\/j.celrep.2020.107762.","DOI":"10.1016\/j.celrep.2020.107762"},{"key":"3310_CR27","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/bjs.11206","volume":"106","author":"I Ubink","year":"2019","unstructured":"Ubink I, Bolhaqueiro ACF, Elias SG, Raats DAE, Constantinides A, Peters NA, et al. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy. Br J Surg. 2019;106:1404\u201314.","journal-title":"Br J Surg"},{"key":"3310_CR28","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/s41416-022-01742-5","volume":"126","author":"J Laoukili","year":"2022","unstructured":"Laoukili J, Constantinides A, Wassenaar ECE, Elias SG, Raats DAE, van Schelven SJ, et al. Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity. Br J Cancer. 2022;126:1824\u201333.","journal-title":"Br J Cancer"},{"key":"3310_CR29","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","volume":"28","author":"KP Rovers","year":"2021","unstructured":"Rovers KP, Wassenaar ECE, Lurvink RJ, Creemers G-JM, Burger JWA, Los M, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28:5311\u201326.","journal-title":"Ann Surg Oncol"},{"key":"3310_CR30","doi-asserted-by":"publisher","first-page":"e030408","DOI":"10.1136\/bmjopen-2019-030408","volume":"9","author":"KP Rovers","year":"2019","unstructured":"Rovers KP, Lurvink RJ, Wassenaar EC, Kootstra TJ, Scholten HJ, Tajzai R, et al. Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC). BMJ Open. 2019;9:e030408.","journal-title":"BMJ Open"},{"key":"3310_CR31","doi-asserted-by":"publisher","first-page":"e044811","DOI":"10.1136\/bmjopen-2020-044811","volume":"11","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Rauwerdink P, Rovers KP, Wassenaar ECE, Deenen MJ, Nederend J, et al. First-line palliative systemic therapy alternated with electrostatic pressurised intraperitoneal aerosol chemotherapy (oxaliplatin) for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, single-arm, phase II study (CRC-PIPAC-II). BMJ Open. 2021;11:e044811.","journal-title":"BMJ Open"},{"key":"3310_CR32","doi-asserted-by":"publisher","first-page":"e077667","DOI":"10.1136\/bmjopen-2023-077667","volume":"14","author":"Vlasakker","year":"2024","unstructured":"Vlasakker VCJ van de, Guchelaar NAD, Heuvel TBM van den, Lurvink RJ, Meerten E van, Bax RJF, et al. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial. BMJ Open. 2024;14:e077667.","journal-title":"BMJ Open"},{"key":"3310_CR33","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.3390\/cancers13215434","volume":"13","author":"E K\u00fc\u00e7\u00fckk\u00f6se","year":"2021","unstructured":"K\u00fc\u00e7\u00fckk\u00f6se E, Wensink GE, Roelse CM, van Schelven SJ, Raats DAE, Boj SF, et al. Mismatch repair status in patient-derived colorectal cancer organoids does not affect intrinsic tumor cell sensitivity to systemic therapy. Cancers. 2021;13:5434.","journal-title":"Cancers"},{"key":"3310_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201323.","journal-title":"Genet Med"},{"key":"3310_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OliverH Lowry","year":"1951","unstructured":"Lowry OliverH, Rosebrough NiraJ, Farr AL, Randall RoseJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265\u201375.","journal-title":"J Biol Chem"},{"key":"3310_CR36","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s002280050505","volume":"54","author":"E Jonsson","year":"1998","unstructured":"Jonsson E, Fridborg H, Nygren P, Larsson R. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients. Eur J Clin Pharm. 1998;54:509\u201314.","journal-title":"Eur J Clin Pharm"},{"key":"3310_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-016-0239-6","volume":"9","author":"\u00c5 Fransson","year":"2016","unstructured":"Fransson \u00c5, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. J Ovarian Res. 2016;9:27.","journal-title":"J Ovarian Res"},{"key":"3310_CR38","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos PA, Cheng S-C, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, et al. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:957\u201368.","journal-title":"Lancet Oncol"},{"key":"3310_CR39","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1021\/acs.jmedchem.3c01917","volume":"67","author":"WC Black","year":"2024","unstructured":"Black WC, Abdoli A, An X, Auger A, Beaulieu P, Bernatchez M, et al. Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500). J Med Chem. 2024;67:2349\u201368.","journal-title":"J Med Chem"},{"key":"3310_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","volume":"21","author":"A Roulston","year":"2022","unstructured":"Roulston A, Zimmermann M, Papp R, Skeldon A, Pellerin C, Dumas-B\u00e9rube \u00c9, et al. RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol Cancer Ther. 2022;21:245\u201356.","journal-title":"Mol Cancer Ther"},{"key":"3310_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep13545","volume":"5","author":"S Checkley","year":"2015","unstructured":"Checkley S, MacCallum L, Yates J, Jasper P, Luo H, Tolsma J, et al. Bridging the gap between in vitro and in vivo: dose and schedule predictions for the atr inhibitor AZD6738. Sci Rep. 2015;5:13545.","journal-title":"Sci Rep"},{"key":"3310_CR42","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti FP, Lau A, Schamus S, Conrads TP, O\u2019Connor MJ, Bakkenist CJ. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6:44289\u2013305.","journal-title":"Oncotarget"},{"key":"3310_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","volume":"19","author":"AM Wengner","year":"2020","unstructured":"Wengner AM, Siemeister G, L\u00fccking U, Lefranc J, Wortmann L, Lienau P, et al. The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage\u2013inducing or repair\u2013compromising therapies in preclinical cancer models. Mol Cancer Ther. 2020;19:26\u201338.","journal-title":"Mol Cancer Ther"},{"key":"3310_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ijrobp.2019.06.2508","volume":"105","author":"K Wickstroem","year":"2019","unstructured":"Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, et al. Preclinical combination studies of an FGFR2 targeted thorium-227 conjugate and the ATR inhibitor BAY 1895344. Int J Radiat Oncol Biol Phys. 2019;105:410\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3310_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10637-012-9815-9","volume":"31","author":"GJ Weiss","year":"2013","unstructured":"Weiss GJ, Donehower RC, Iyengar T, Ramanathan RK, Lewandowski K, Westin E, et al. Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg\/m2 every 21 days in patients with cancer. Invest N Drugs. 2013;31:136\u201344.","journal-title":"Invest N Drugs"},{"key":"3310_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","volume":"32","author":"C King","year":"2014","unstructured":"King C, Diaz H, Barnard D, Barda D, Clawson D, Blosser W, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest N Drugs. 2014;32:213\u201326.","journal-title":"Invest N Drugs"},{"key":"3310_CR47","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther. 2009;8:2992\u20133000.","journal-title":"Mol Cancer Ther"},{"key":"3310_CR48","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, et al. Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine \u00b1 cisplatin in patients with advanced solid tumours. Br J Cancer. 2021;125:510\u20139.","journal-title":"Br J Cancer"},{"key":"3310_CR49","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, et al. Phase I Trial of First-in-Class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol. 2020;38:3195\u2013204.","journal-title":"J Clin Oncol"},{"key":"3310_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100017","volume":"2","author":"FM Barnieh","year":"2021","unstructured":"Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. Curr Res Pharm Drug Discov. 2021;2:100017.","journal-title":"Curr Res Pharm Drug Discov"},{"key":"3310_CR51","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, et al. First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors. Clin Cancer Res. 2024;30:2057\u201367.","journal-title":"Clin Cancer Res"},{"key":"3310_CR52","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Fontana E, Lee EK, Spigel DR, H\u00f8jgaard M, Lheureux S, et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023;29:1400\u201311.","journal-title":"Nat Med"},{"key":"3310_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 2021;11:80\u201391.","journal-title":"Cancer Discov"},{"key":"3310_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3131-x","volume":"17","author":"B Laquente","year":"2017","unstructured":"Laquente B, Lopez-Martin J, Richards D, Illerhaus G, Chang DZ, Kim G, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 2017;17:137.","journal-title":"BMC Cancer"},{"key":"3310_CR55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","volume":"34","author":"G Scagliotti","year":"2016","unstructured":"Scagliotti G, Kang JH, Smith D, Rosenberg R, Park K, Kim S-W, et al. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Invest N Drugs. 2016;34:625\u201335.","journal-title":"Invest N Drugs"},{"key":"3310_CR56","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3390\/cancers13040795","volume":"13","author":"L Gorecki","year":"2021","unstructured":"Gorecki L, Andrs M, Korabecny J. Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 axis in cancer. Cancers. 2021;13:795.","journal-title":"Cancers"},{"key":"3310_CR57","doi-asserted-by":"publisher","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","volume":"20","author":"Q Tang","year":"2023","unstructured":"Tang Q, Wang X, Wang H, Zhong L, Zou D. Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biol Med. 2023;20:915\u201321.","journal-title":"Cancer Biol Med"},{"key":"3310_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux S, Cristea MC, Bruce JP, Garg S, Cabanero M, Mantia-Smaldone G, et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:281\u201392.","journal-title":"Lancet"},{"key":"3310_CR59","first-page":"24","volume":"0","author":"JF Liu","year":"2025","unstructured":"Liu JF, Colombo N, Oza AM, Frenel J-S, Corr BR, Rubinstein MM, et al. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. J Clin Oncol. 2025;0:24\u201301606.","journal-title":"J Clin Oncol"},{"key":"3310_CR60","doi-asserted-by":"publisher","unstructured":"Qian J, Liao G, Chen M, Peng R-W, Yan X, Du J, et al. Advancing cancer therapy: new frontiers in targeting DNA damage response. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1474337.","DOI":"10.3389\/fphar.2024.1474337"},{"key":"3310_CR61","first-page":"1","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023;8:1\u201326.","journal-title":"Signal Transduct Target Ther"},{"key":"3310_CR62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1515\/pp-2022-0116","volume":"7","author":"M Raoof","year":"2022","unstructured":"Raoof M, Sullivan KM, Frankel PH, Fakih M, Synold TW, Lim D, et al. Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. Pleura Peritoneum. 2022;7:169\u201377.","journal-title":"Pleura Peritoneum"},{"key":"3310_CR63","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.3390\/jcm11102840","volume":"11","author":"MM Harper","year":"2022","unstructured":"Harper MM, Kim J, Pandalai PK. Current trends in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal disease from appendiceal and colorectal malignancies. J Clin Med. 2022;11:2840.","journal-title":"J Clin Med"},{"key":"3310_CR64","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1016\/j.ejca.2008.07.038","volume":"44","author":"RD Issels","year":"2008","unstructured":"Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44:2546\u201354.","journal-title":"Eur J Cancer"},{"key":"3310_CR65","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.3390\/cancers13133114","volume":"13","author":"W Ceelen","year":"2021","unstructured":"Ceelen W, Demuytere J, de Hingh I. Hyperthermic intraperitoneal chemotherapy: a critical review. Cancers. 2021;13:3114.","journal-title":"Cancers"},{"key":"3310_CR66","doi-asserted-by":"publisher","unstructured":"Helderman RFCPA, L\u00f6ke DR, Verhoeff J, Rodermond HM, Bochove et al. The temperature-dependent effectiveness of platinum-based drugs mitomyc GGW van, Boon M, in-C and 5-FU during hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer cell lines. Cells 2020;9. https:\/\/doi.org\/10.3390\/cells9081775.","DOI":"10.3390\/cells9081775"},{"key":"3310_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0305-7372(76)80019-9","volume":"3","author":"ST Crooke","year":"1976","unstructured":"Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev. 1976;3:121\u201339.","journal-title":"Cancer Treat Rev"},{"key":"3310_CR68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/bjc.2011.498","volume":"106","author":"DC Gilbert","year":"2012","unstructured":"Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer. 2012;106:18\u201324.","journal-title":"Br J Cancer"},{"key":"3310_CR69","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrd1287","volume":"3","author":"J Graham","year":"2004","unstructured":"Graham J, Muhsin M, Kirkpatrick P. Oxaliplatin. Nat Rev Drug Discov. 2004;3:11\u201312.","journal-title":"Nat Rev Drug Discov"},{"key":"3310_CR70","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1007\/PL00012514","volume":"59","author":"AM Di Francesco","year":"2002","unstructured":"Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci CMLS. 2002;59:1914\u201327.","journal-title":"Cell Mol Life Sci CMLS"},{"key":"3310_CR71","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.3390\/cancers14122928","volume":"14","author":"Q Wang","year":"2022","unstructured":"Wang Q, Shen X, Chen G, Du J. Drug resistance in colorectal cancer: from mechanism to clinic. Cancers. 2022;14:2928.","journal-title":"Cancers"},{"key":"3310_CR72","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/bjc.2011.449","volume":"105","author":"D Bose","year":"2011","unstructured":"Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer. 2011;105:1759\u201367.","journal-title":"Br J Cancer"},{"key":"3310_CR73","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/biomedicines12010183","volume":"12","author":"M Eslami","year":"2024","unstructured":"Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B. Overcoming chemotherapy resistance in metastatic cancer: a comprehensive review. Biomedicines. 2024;12:183.","journal-title":"Biomedicines"},{"key":"3310_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100633","volume":"296","author":"EC Sutton","year":"2021","unstructured":"Sutton EC, DeRose VJ. Early nucleolar responses differentiate mechanisms of cell death induced by oxaliplatin and cisplatin. J Biol Chem. 2021;296:100633.","journal-title":"J Biol Chem"},{"key":"3310_CR75","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23:461\u201371.","journal-title":"Nat Med"},{"key":"3310_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111728","volume":"41","author":"J Laoukili","year":"2022","unstructured":"Laoukili J, Van Schelven S, K\u00fc\u00e7\u00fckk\u00f6se E, Verheem A, Goey K, Koopman M, et al. BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site-specific metastasis by stimulating glutathione synthesis. Cell Rep. 2022;41:111728.","journal-title":"Cell Rep"},{"key":"3310_CR77","doi-asserted-by":"publisher","first-page":"624954","DOI":"10.3389\/fonc.2020.624954","volume":"10","author":"Z-X Wu","year":"2020","unstructured":"Wu Z-X, Yang Y, Zeng L, Patel H, Bo L, Lin L, et al. Establishment and characterization of an irinotecan-resistant human colon cancer cell line. Front Oncol. 2020;10:624954.","journal-title":"Front Oncol"},{"key":"3310_CR78","first-page":"946","volume":"4","author":"S Ozawa","year":"2021","unstructured":"Ozawa S, Miura T, Terashima J, Habano W. Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review. Cancer Drug Resist. 2021;4:946\u201364.","journal-title":"Cancer Drug Resist"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03310-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03310-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:02:59Z","timestamp":1770976979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03310-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,5]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03310-z","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided informed consent to their tumor tissues being used for PMDO generation and subsequent molecular and genetic analysis. PDMO samples have been collected with patient consent as part of the CRC-PIPAC studies (NCT03246321, NL8303), Interact trial (NCT06003998), or unpublished collaboration (ORCAPM) between UMC Utrecht and Catharina Hospital Eindhoven. Which all have been approved by the Medical Review Ethics Committee (NL60405.100.17, R19.087, NL81672.100.22, ORCA-PM-CZE). The studies were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}}]}}